Table 3 Univariate survival analysis for epithelial CXC-chemokine expression

	All patients ( n =254)				Stage II patients ( n =163)				Stage III patients ( n =91)
	Recurrence-free survival		Overall survival		Recurrence-free survival		Overall survival		Recurrence-free survival		Overall survival
	Recurrences/ no. of patients	log-rank ( P)	Deaths/ no. of patients	log-rank ( P)	Recurrences/ no. of patients	log-rank ( P)	Deaths/ no. of patients	log-rank ( P)	Recurrences/ no. of patients	log-rank ( P)	Deaths/ no. of patients	log-rank ( P)
Tumour stage
II	40/163		51/163
III	51/91	<0.001	55/91	<0.001
Tumour epithelial CXCR1
Absent/weak	7/28		9/28		6/19		7/19		1/9		2/9
Moderate	63/160	0.379	69/160	0.586	59/103	0.156	65/103	0.146	4/57	0.675	4/57	0.106
Strong	10/22		11/22		10/14		11/14		0/8		0/8
Tumour epithelial CXCR2
Absent/weak	8/18		9/18		8/13		9/13		0/5		0/5
Moderate	45/120	0.748	47/120	0.482	40/74	0.879	42/74	0.880	5/46	0.314	5/46	0.698
Strong	18/51		25/51		18/36		23/36		0/15		2/15
Tumour epithelial CXCL1
Absent/weak	9/30		9/30		8/14		9/14		1/16		0/16
Moderate	63/162	0.546	71/162	0.409	61/107	0.585	66/107	0.628	2/55	0.041	5/55	0.061
Strong	8/21		9/21		6/14		7/14		2/7		2/7
Tumour inflammatory infiltrate CXCL8
Negative	42/79		39/79		38/50		36/50		4/29		3/29
Positive	42/149	<0.001	58/149	0.150	41/99	<0.001	54/99	0.029	1/50	0.040	4/50	0.806

Quick links

Search